ABC | Volume 111, Nº3, Setembro 2018

Diretrizes Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda Arq Bras Cardiol. 2018; 111(3):436-539 476. Theodoropoulos TA, Bestetti RB, Otaviano AP, Cordeiro JA, Rodrigues VC, Silva AC. Predictors of all-cause mortality in chronic Chagas heart disease in the current era of heart failure therapy. Int J Cardiol. 2008;128(1):22-9. 477. Barbosa AP, Cardinalli-Neto A, Otaviano AP, Rocha BF, Bestetti RB. Comparison of outcome between Chagas cardiomyopathy and idiopathic dilated cardiomyopathy. Arq Bras Cardiol. 2011;97(6):517-25. 478. Vilas Boas LG, Bestetti RB, Otaviano AP, Cardinalli-Neto A, Nogueira PR. Outcome of Chagas cardiomyopathy in comparison to ischemic cardiomyopathy. Int J Cardiol. 2013;167(2):486-90. 479. Bestetti RB, Otaviano AP, Fantini JP, Cardinalli-Neto A, Nakazone MA, Nogueira PR. Prognosis of patients with chronic systolic heart failure: Chagas disease versus systemic arterial hypertension. Int J Cardiol. 2013;168(3):2990-1. 480. Bertolino ND, Villafanha DF, Cardinalli-Neto A, Cordeiro JA, Arcanjo MA, Theodoropoulos TA, et al. Prognostic impact of Chagas disease in patients awaiting heart transplantation. J Heart Lung Transplant. 2010;29(4):449-53. 481. Botoni FA, Poole-Wilson PA, Ribeiro AL, Okonko DO, Oliveira BM, Pinto AS, et al. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J. 2007;153(4):544.e1-8. 482. Morillo CA, Marin-Neto JA, AvezumA, Sosa-Estani S, Rassi-Jr A, Rosas F, et al; BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas cardiomyopathy. N Engl J Med. 2015;373(14):1295-306. 483. Lima MM, Rocha MO, Nunes MC, Souza L, Costa HS, Alencar MC, et al. A randomized trial of the effects of exercise training in Chagas cardiomyopathy. Eur J Heart Fail. 2010;12(8):866-73. 484. Bestetti RB, Otaviano AP, Cardinalli-Neto A, Rocha BF, Theodoropoulos TA, Cordeiro JA. Effects of B-Blockers on outcome of patients with Chagas cardiomyopathywithchronicheartfailure.IntJCardiol.2011;151(2):205-8. 485. Issa VS, Amaral AF, Cruz FD, Ferreira SM, Guimarães GV, Chizzola PR, et al. B-Blocker therapy andmortality of patients with Chagas cardiomyopathy. A subanalysis of the REMADHE prospective trial. Circ Heart Fail. 2010;3(1):82-8. 486. Ramires FJ, Salemi VM, Ianni BM, Fernandes F, Martins DG, Bilate A, et al. Aldosterone antagonism in na inflammatory state: evidence formyocardial protection. J Renin Angiotensin Aldosterone Syst. 2006;7(3):162-7. 487. Ferrari SJ, Bestetti RB, Cardinalli-Neto A, Bortoluzzi TB. Digoxin serum levels in patients with Chagas cardiomyopathy and heart failure. Rev Soc Bras Med Trop. 2010;43(4):496-9. 488. Nunes MC, Kreuser LJ, Ribeiro AL, Souza GR, Costa HS, Botoni FA, et al. Prevalence and risk factors of embolic cerebrovascular events associated with Chagas heart disease. Glob Heart. 2015;10(3):151-7. 489. Ayub-Ferreira SM, Mangini S, Issa VS, Cruz FD, Bacal F, Guimarães GV, et al. Mode of death on Chagas heart disease: comparison with other etiologies. Plos Negl Trop Dis. 2013;7(4):e2176. 490. Cardinalli-Neto A, Lorga-Filho A, Silva EF, Lima RP, Palmegiani E, Bestetti RB. Clinical predictors of inducible sustained ventricular tachycardia during Electrophysiologic study in patients with chronic Chagas heart disease. Int J Cardiol Heart Vasc. 2015 Oct 19;9:85-8. 491. SilvaRT,Martinelli-FilhoM,LimaCE,MartinsDG,NishiokaAS,PedrosaAA,et al.Functionalbehaviorofpatientswithconventionalpacemakersundergoing cardiac resynchronization. Arq Bras Cardiol. 2008;90(2);138-43. 492. AraujoEF,ChamianEG,PeroniAP,PereiraWL,GandraSM,RivettiLA.Cardiac resynchronizationtherapy inpatientswithchronicChagascardiomyopathy: long-term followup. Rev Bras Cir Cardiovasc. 2014;29(1):31-6. 493. Cardinalli-Neto A, Nakazone MA, Grassi LV, Tavares BG, Bestetti RB. Implantable cardioverter-defibrillator therapy for primary prevention of sudden cardiac death in patients with severe Chagas cardiomyopathy. Int J Cardiol. 2011;150(1):94-5. 494. Pereira FT, Rocha EA, Monteiro MP, Neto AC, Daher E, Sobrinho CR, et al. Long-term follow-up of patients with chronic Chagas disease and implantable cardioverter-defibrillator. Pacing Clin Electrophysiol. 2014;37(6):751-6. 495. Bocchi EA, Fiorelli A; First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. The paradox of survival results after heart transplantation caused by Trypanosoma cruzi. Ann Thorac Surg. 2001;71(6):1833-8. 496. Bestetti RB, Souza TR, Lima MF, Theodoropoulos TA, Cordeiro JA, Burdmann EA. Effects of a mycophenolate mofetil-based immunosuppressive regimen in Chagas heart transplant recipients. Transplantation. 2007;84(3):441-2. 497. AvilaWS, Rossi EG, Ramires JA, Grinberg M, BortolottoMR, ZugaibM, et al. Pregnancy in patients with heart disease: experience with 1,000 cases. Clin Cardiol. 2003;26(3):135-42. 498. Mogos MF, Piano MR, McFarlin BL, Salemi JL, Liese KL, Briller JE. Heart failure in pregnant woman: a concern across the pregnancy continuum. Circ Heart Fail. 2018;11(1):e004005. 499. VettoriDV,RohdeLE,ClausellN.Asymptomatic leftventriculardysfunction in puerperal women: an echocardiographic-based study. Int J Cardiol. 2011;149(3):353-7. 500. Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation. 2016;133(14):1397-409. 501. Habli M, O’Brien T, Nowack E, Khoury S, Barton JR, Sibai B. Peripartum cardiomyopathy: prognostic factors for long-termmaternal outcome. Am J Obstet Gynecol. 2008;199(4):415.e1-5. 502. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, et al; ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of theEuropeanSocietyofCardiology(ESC).EurHeartJ.2011;32(24):3147-97. 503. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121(13):1465-73. 504. Hilfiker-KleinerD,HaghikiaA,BerlinerD,Vogel-ClaussenJ,SchwabJ,Franke A, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017;38(35):2671-9. 505. Fi n s t e r e r J, S t ö l l b e r g e r C , Towb i n J A . L e f t v e n t r i c u l a r noncompactioncardiomyopathy: cardiac, neuromuscular, and genetic factors. Nat Rev Cardiol. 2017;14(4):224-37. 506. Chebrolu LH, Mehta AM, Nanda NC. Noncompaction cardiomyopathy: The role of advanced multimodality imaging techniques in diagnosis and assessment. Echocardiography. 2017;34(2):279-89. 507. Ritter M, Oechslin E, Sütsch G, Attenhofer C, Schneider J, Jenni R. Isolated noncompactionofthemyocardiuminadults.MayoClinProc.1997;72(1):26-31. 508. Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, et al; American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council onEpidemiology and Prevention; and Council on Quality of Care and Outcomes Research. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 2016;134(23):e579-646. 509. Stähli BE, Gebhard C, Biaggi P, Klaassen S, Valsangiacomo Buechel E, Attenhofer Jost CH, et al. Left ventricularnon-compaction: prevalence in congenital heart disease. Int J Cardiol. 2013;167(6):2477-81. 510. Chin TK, Perloff JK, Williams RG, Jue K, Mohrmann R. Isolated noncompaction of left ventricular myocardium: a study of eight cases. Circulation. 1990;82(2):507-13. 531